Drug-Linker Conjugates for ADC
Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.
The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.
ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.
Drug-Linker Conjugates for ADC Isoform Specific Products
-
Drug-Linker Conjugates for ADC
(327)
View all products
-
Auristatin
(45)
View all products
-
Camptothecins
(33)
View all products
-
Daunorubicins/
Doxorubicins (5)View all products
-
Duocarmycins
(8)
View all products
-
Maytansinoids
(19)
View all products
-
Pyrrolobenzodiazepines
(5)
View all products
-
Traditional Cytotoxic Agents
(31)
View all products
-
Dual payloads
(5)
View all products
All Product Categories
-
Drug-Linker Conjugates for ADC Related Products (500)
Related Products (500)
-
Drug-Linker Conjugates for ADC Isoform Comparison
-
Deruxtecan analog 2 monoTFA
0 ImagesCat. No.: HY-128979BCAS No.: 2758874-59-6Deruxtecan analog 2 (monoTFA) is a homolog of Deruxtecan (HY-13631E), a conjugate of the ADC toxin DX-8951 derivative (Dxd) with an ADC Linker.
-
Mal-Val-Lys-PAB-MMAE
0 ImagesCat. No.: HY-177307CAS No.: 2435608-81-2Mal-Val-Lys-PAB-MMAE is a drug-linker conjugate for ADC. Mal-Val-Lys-PAB-MMAE consists of a Tubulin inhibitor (MMAE) (HY-15162) and a linker (Mal-Val-Lys-PAB). Mal-Val-Lys-PAB-MMAE can be used for synthesis of ADCs.
-
SG3400 delate(Mal-amido-PEG8)
0 ImagesCat. No.: HY-147231CAS No.: 2125685-22-3SG3400 delate (Mal-amido-PEG8) (compound 21) is an intermediate for the synthesis of ADC molecules. SG3400 delete is an effective toxin molecule with anticancer activity. SG3400 delete can be used in cancer research.
-
N-(endo-BCN-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
0 ImagesCat. No.: HY-177684N-(endo-BCN-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(endo-BCN-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
-
Maleimide-Ph(3,5-F)-PEG4-Val-Ala-MF-6
0 ImagesCat. No.: HY-175216Maleimide-Ph(3,5-F)-PEG4-Val-Ala-MF-6 is a drug-linker conjugate for ADC. Maleimide-Ph(3,5-F)-PEG4-Val-Ala-MF-6 consists of a topoisomerase 1 inhibitor (Topi MF-6) (HY-175203) and a cleavable linker (Maleimide-Ph(3,5-F)-PEG4-Val-Ala) (HY-175218). Maleimide-Ph(3,5-F)-PEG4-Val-Ala-MF-6 can be used for synthesis of ADCs.
-
MC-GGFG-AM-(10NH2-11F-Camptothecin)
0 ImagesCat. No.: HY-156514CAS No.: 2987938-97-4MC-GGFG-AM-(10NH2-11F-Camptothecin) is an antibody drug conjugates (ADC). MC-GGFG-AM-(10NH2-11F-Camptothecin) binds to the anti-TROp-2 antibody sacituzumab via a hydrolysable pH-sensitive linker and has anti-tumor activity. MC-GGFG-AM-(10NH2-11F-Camptothecin) can be used for cancer research.
-
MC-amide-C2-amide-(β-D-GlcUA)-amide-PEG1-CH2-CC-885
0 ImagesCat. No.: HY-182813CAS No.: 2874334-41-3MC-amide-C2-amide-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 is a Drug-Linker Conjugates for ADC composed of CC-885 (HY-101488) and a linker. MC-amide-C2-amide-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 conjugates with GemtUZUmab (HY-P99971) to synthesize an ADC (Compound ADC-2). ADC-2 exhibits anti-tumor activity in a leukemia MV-4-11 xenograft model.
-
DM21-L-G NHS ester
0 ImagesCat. No.: HY-185569CAS No.: 2776103-81-0DM21-L-G NHS ester is a toxin molecule-linker conjugate that can be used for the synthesis of ADCs, such as Opugotamig olatansine (HY-185427).
-
Aminooxy CatB-LXR
0 ImagesCat. No.: HY-144554CAS No.: 1779524-93-4Aminooxy CatB-LXR (compound 10) is a agent-linker conjugates for ADC.
-
SDP-LIV1 drug-linker
0 ImagesCat. No.: HY-181697CAS No.: 2768037-87-0SDP-LIV1 drug-linker is a drug-linker conjugate formed by the condensation of a linker and a topoisomerase I inhibitor. It can be used for the preparation of ADCs, such as SDP-LIV1.
-
ADC 38 drug linker
0 ImagesCat. No.: HY-180563ADC 38 drug linker is a drug linker coupling agent used for ADCs, consisting of a CD4 mimic and a linker. ADC 38 drug linker can be used to synthesize antibody-drug conjugates (ADCs), such as ADC 38.
-
OH-Glu-Val-Cit-PAB-MMAE-d8
0 ImagesCat. No.: HY-148245SOH-Glu-Val-Cit-PAB-MMAE-d8 is the deuterated-labeled OH-Glu-Val-Cit-PAB-MMAE (HY-148245). OH-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (OH-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).
-
MC-Val-Cit-Gly-exatecan-β-D-glucopyranosiduronic acid
0 ImagesCat. No.: HY-164380CAS No.: 3023709-42-1MC-Val-Cit-Gly-exatecan-β-D-glucopyranosiduronic acid (example 13) is a drug-linker conjugate that consists of a DNA topoisomerase I inhibitor Exatecan (HY-13631) and a linker (HY-180841). MC-Val-Cit-Gly-exatecan-β-D-glucopyranosiduronic acid can be used in synthesis of ADC.
-
TLR7/8 agonist 4 hydroxy-PEG10-acid
0 ImagesCat. No.: HY-139018CAS No.: 2388520-17-8TLR7/8 agonist 4 hydroxy-PEG10-acid (compound 9) is a drug-linker conjugates for ADC with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the non-cleavable ADC linker hydroxy-PEG10-acid (HY-133307).
-
Glucocorticoid receptor agonist-4 Ala-Ala-Mal
0 ImagesCat. No.: HY-160180CAS No.: 3014393-37-1Glucocorticoid receptor agonist-4 Ala-Ala-Mal (Compound Preparation 9) is an anti-human TNFα antibody-glucocorticoid receptor agonist (GC) conjugate. Glucocorticoid receptor agonist-4 Ala-Ala-Mal can be used in the study of autoimmune and inflammatory diseases.
-
Maleimide-PEG8-Val-Ala-PAB-SNS032
0 ImagesCat. No.: HY-161780Maleimide-Val-Ala-PAB-SNS032 is a conjugate of ADC toxin and linker. SNS032 is an inhibitor for CDK, inhibiting the cell cycle at G1/S phase and cell viability of cancer cells. Maleimide-Val-Ala-PAB is a cleavable ADC linker. Maleimide-Val-Ala-PAB-SNS032 can be utilized for the synthesis of ADC molecules.
-
DL149
0 ImagesCat. No.: HY-183253DL149 is a component of an antibody-drug conjugate (ADC) formed by conjugating the eIF4A inhibitor FD236 (HY-186186) with an ADC linker, and exhibits potential antitumor activity. DL149 can bind to an anti-HER2 antibody to form a complete ADC molecule, which precisely binds to the HER2 receptor on the surface of tumor cells. After internalization into cells, it releases the eIF4A inhibitor payload. DL149 irreversibly blocks the mRNA translation process in tumor cells, thereby inhibiting tumor cell proliferation and inducing their death. DL149 exhibits in vivo antitumor activity in the SK-OV-3 xenograft tumor model, and can be used for the research of HER2-positive solid tumors.
-
MC-cBu-Cit-seco-CBI dimer
0 ImagesCat. No.: HY-185492CAS No.: 1799659-90-7MC-cBu-Cit-seco-CBI dimer (Compound 10) is a conjugate of an ADC drug toxin molecule and a linker, which consists of a DNA alkylating agent connected to a reactive maleimide via a protease-cleavable peptidomimetic linker.
-
MC-Val-Ala-PAB-NH-Ph-CO-piperidin-4-ol-C4-NH-cyanoguanidine
0 ImagesCat. No.: HY-187360CAS No.: 3087291-81-1MC-Val-Ala-PAB-NH-Ph-CO-piperidin-4-ol-C4-NH-cyanoguanidine is a cathepsin B-cleavable linker-payload, with Nampt-IN-22 (HY-187336) as its toxin moiety. MC-Val-Ala-PAB-NH-Ph-CO-piperidin-4-ol-C4-NH-cyanoguanidine can be used for the synthesis of ADC.
-
AmPEG6C2-Aur0131
0 ImagesCat. No.: HY-111555CAS No.: 1650569-94-0AmPEG6C2-Aur0131 is a agent-linker conjugate for ADC (anti-CXCR4 ADC) with potent antitumor activity by using Aur0131 (an auristatin microtubule inhibitor), linked via the non-cleavable linker AmPEG6C2.
